Lymphoma

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma.

We’ve all heard the jokes about hospital food.

A phase 2 trial found that some patients with classical Hodgkin lymphoma saw a nearly 74% probability of second remission due to retreatment with Keytruda.

While much progress has been made in treating blood cancers like lymphoma, I know that there is still far more work to be done.

The very first blog I ever wrote for CURE asked the question, “Why me?”

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.

I don’t know about you, but music moves me. Literally. It makes me move.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.

Here’s a look back at blood cancer approvals from the summer of 2023.

A phase 1 clinical trial just launched and will test the novel agent, CLN-978, for relapsed/refractory B-cell non-Hodgkin lymphoma.

One of the most common side effects of cancer treatment must be the chills, feeling cold all the time.

When paired with the chemotherapy combination doxorubicin, vinblastine and dacarbazine, Keytruda resulted in 100% overall survival in the findings from a new study of adult patients with classic Hodgkin lymphoma.

Being treated for Hodgkin lymphoma during childhood can result in fertility declines, a recent study shows.

Patients with advanced cancers who live in states that expanded Medicaid were more likely to receive early palliative care, although utilization remains low in the U.S.

Patients with depression or anxiety at the time of a diffuse large B-cell lymphoma diagnosis tended to have worse survival, recent research showed.

Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.

Here’s an overview of the new cancer regimens that gained Food and Drug Administration (FDA) approval in the spring of this year.

A significant majority of patients with early-stage classical Hodgkin lymphoma demonstrated a complete response to treatment with Adcetris, Opdivo and chemotherapy.

Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.

From YouTuber Hank Green announcing his lymphoma diagnosis, to Jeff Bridges, Martina Navratilova and Leanne Hainsby giving updates on their cancer, here’s what’s happening in the oncology space this week.

“Nobody’s going to fight for your life the way you’re going to fight for your life,” Hodgkin’s lymphoma survivor, Paula Ngon, told CURE®.

The FDA approval of Epkinly also includes a subset of patients with indolent lymphoma-related DLBCL and those with high-grade B-cell lymphoma after two or more systemic therapies.

Cryopreserved stem cells led to a higher rate of relapse in patients with blood cancer, though there was no difference in survival, research showed.

From ‘Pokémon’ actor James Carter Cathcart stepping away from the show to undergo cancer treatment to Ahmad Jamal and Otis Redding III dying of cancer, here’s what’s happening in the oncology space this week.

Cancer-related can be consuming, so my sister and I make sure to celebrate the little victories along the way.

The Food and Drug Administration approved Polivy plus Rituxan, cyclophosphamide, doxorubicin and prednisone for patients with previously untreated diffuse large B-cell lymphoma — marking the first new regimen in nearly two decades for this patient population.

One patient was able to access a therapy for follicular lymphoma before it was approved by the FDA, which allowed him to help future patients through his experience.

Omisirge is an umbilical cord blood-based therapy that may prevent infection in patients with blood cancer undergoing stem cell transplant.

I learned that self-advocacy is not about proving an oncology wrong or deciding that one drug is better than the other. It’s about speaking up for what you think is right.